First International Melanoma Research Congress

Last Modified: January 19, 2003

Conference Dates: June 21-24, 2003
Conference Location: Wyndham Franklin Plaza Hotel in Philadelphia

Sponsoring Group: Foundation for Melanoma Research

Conference Web Page URL:

Topics Covered: Immunology, Epidemiology, Biology, Molecular Biology and Tumor Microenvironment.

Conference Objectives: To provide the community of melanoma researchers with a comprehensive overview of the current state of research.

Who Should Attend: Physicians, Medical Oncologists, Traslational Researchers, Basic Researchers

Conference Agenda: The congress will begin on Saturday evening, June 21st, 2003 with keynote addresses by two prominent members of basic and translational melanoma fields. On Sunday and Monday, June 22nd and 23rd there will be plenary sessions in the morning and afternoon, each followed by three concurrent sessions for more detailed discussions. The last day's program on Tuesday, June 24 will have the same format but is restricted to the morning. Poster sessions in the evenings/late afternoons of Sunday and Monday will provide all participants the opportunity to present their research. The 5 plenary sessions will have 5 speakers each in immunology, epidemiology, biology, molecular biology and the tumor microenvironment. The 13 concurrent sessions will cover research areas that are evenly divided among the different research topics. On Monday evening the Melanoma Research Society will be inaugurated. In future years it will be the main sponsor of research meetings.! The Second Melanoma Research Congress will be held in 2005.

Registration Information: Register online at, by mail by writing to FMR, 3601 Spruce Street, Room 489, Philadelphia, PA 19104

Conference Fees: Physicians and Scientists before 4/11: $350 and Students: $200 After 4/11 the fee schedule changes.

Continuing Education: No

Related News

No Clinical Benefit Found for Occult Cancer CT Screening in VTE

Jun 23, 2015

Prevalence of occult cancer low among patients with first unprovoked venous thromboembolism

Metastatic Melanoma Responds to First-Line Interleukin-21

Aug 24, 2012

Overall response rate of 22.5 percent, independent of BRAF mutation, IL-21 receptor expression

AACR: Coffee Tied to Lower Basal Cell Carcinoma Risk

Oct 26, 2011

Inverse link between coffee intake and basal cell, not squamous cell carcinoma or melanoma risk